Ventilator-associated pneumonia

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

Retrieved on: 
Thursday, January 18, 2024

LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for pneumonia patients.

Key Points: 
  • LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for pneumonia patients.
  • The Pneumonia Direct Pilot study is a prospective, observational, diagnostic, feasibility study to determine the accuracy of multiple pathogen- and host-directed tests for the diagnosis of ventilator-associated pneumonia (VAP).
  • “I am elated that the innovative research leaders of Antibacterial Resistance Leadership Group are collaborating with T2 Biosystems to evaluate direct-from-blood diagnostic technology for the management of patients with pneumonia.
  • The extremely low level of detection by T2 Biosystems’ technology (“T2MR”) in whole blood (1 – 11 CFU/mL) has been effective in detecting secondary infections.

Ultrahuman Revolutionizes Home Health with the Launch of Ultrahuman Home

Retrieved on: 
Tuesday, January 9, 2024

The pioneer in wearable tech unveils a ground-breaking Ultrahuman Home device at CES 2024

Key Points: 
  • Unveiled at CES 2024 in January, Ultrahuman Home introduces a new capability for individuals to track and enhance the health of their living spaces.
  • Personalizing or changing these markers' basis recommendations from the Ultrahuman home platform is expected to help improve the passive factors that affect an individual's health.
  • Ultrahuman Home will help individuals to track and enhance the health of their living spaces.
  • This on-body and off-body health tracking integration is the first time ever in the health monitoring space," said Mohit Kumar, Founder and CEO of Ultrahuman.

Ondine Biomedical’s nasal photodisinfection named as leading photonics biomedical technology for its potential to safely combat AMR

Retrieved on: 
Monday, November 13, 2023

Ondine Biomedical’s Steriwave nasal photodisinfection technology has been shortlisted in the biomedical category of the 2024 international society for optics and photonics SPIE Prism Awards.

Key Points: 
  • Ondine Biomedical’s Steriwave nasal photodisinfection technology has been shortlisted in the biomedical category of the 2024 international society for optics and photonics SPIE Prism Awards.
  • Nasal photodisinfection is a painless, five-minute treatment that uses a patented photosensitive agent and specific, non-UV light to trigger photochemical reactions that produce reactive oxygen species.
  • Ondine CEO, Carolyn Cross, comments, “It is fantastic to see photodisinfection receiving wider recognition as a technology that will be transformative for the future of healthcare.
  • I’m looking forward to congratulating all the finalists and winners at our celebration at Photonics West in January.”

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, November 3, 2023

LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Key Points: 
  • OTCQB companies must be current in their financial reporting and undergo an annual verification and management certification process.
  • We remain optimistic of successful outcomes from these efforts in the coming months,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.
  • Due to fair value option valuation of our notes payable, there was no interest expense recorded during the third quarter of 2023.
  • Other Income: Other income increased to $26,000 for the quarter ended September 30, 2023, compared to approximately $23,000 for the quarter ended September 30, 2022.

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

Retrieved on: 
Tuesday, June 20, 2023

“The data presented at ASM Microbe is quite powerful.

Key Points: 
  • “The data presented at ASM Microbe is quite powerful.
  • Both dose regimens of CF-370 in addition to amikacin significantly reduced bacteria counts compared to all other treatment groups (p≤0.0001).
  • The results of this study reproduce the efficacy seen in previously released data presented at ECCMID 2023 further demonstrating the bactericidal power of CF-370 against XDR strains of Gram-negative pathogens.
  • The results of this study reinforce previously released data demonstrating the power of both CF-296 and exebacase when delivered locally in the rabbit osteomyelitis model.

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, June 8, 2023

LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023.

Key Points: 
  • LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023.
  • “Our first quarter results demonstrate the continued progress and momentum of Aridis Pharmaceuticals.
  • First Quarter 2023 Financial Results:
    Cash: Total cash, cash equivalents and restricted cash as of March 31, 2023, were approximately $1.8 million.
  • Change in Other Comprehensive Income: Change in other comprehensive income increased by approximately $861,000 for the quarter ended March 31, 2023 from $0 for the quarter ended March 31, 2022.

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

Retrieved on: 
Tuesday, May 23, 2023

Innoviva Specialty Therapeutics is focused on delivering innovative therapies in critical care and infectious disease.

Key Points: 
  • Innoviva Specialty Therapeutics is focused on delivering innovative therapies in critical care and infectious disease.
  • “XACDURO is the first pathogen-targeted therapy approved to treat hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter.
  • The FDA approval of XACDURO marks an important milestone in our aim to deliver differentiated therapies to critically ill patients who have limited treatment options,” said David Altarac, MD, Chief Medical Officer, Innoviva Specialty Therapeutics.
  • “Acinetobacter poses a significant danger to hospitalized patients, who are generally very ill and particularly susceptible to infections.

Global Surface Disinfectant Market Report 2023: Increasing Rates of Contamination/Health Risks Fuel the Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 18, 2023

The "Surface Disinfectant Market, by Type, by Composition, by Application, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Surface Disinfectant Market, by Type, by Composition, by Application, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The need for surface disinfectants will increase as a consequence of increasing concern about hospital-acquired infections are some of the factors contributing to the market growth.
  • Increase the number of government-funded initiatives aimed at raising consumer awareness are some other factors contributing to the market growth.
  • Because of these government regulations, rising hygiene awareness has boosted the need for surface disinfectants and is anticipated to fuel market expansion.

ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens

Retrieved on: 
Thursday, April 20, 2023

“The data presented on CF-370 at ECCMID should not be understated.

Key Points: 
  • “The data presented on CF-370 at ECCMID should not be understated.
  • Amikacin alone did not demonstrate a significant reduction in bacterial density in the lungs compared to the vehicle controls (as expected for this amikacin-resistant strain).
  • However, a single dose of CF-370 alone, and in addition to amikacin, significantly reduced bacteria counts compared to vehicle controls.
  • In this in vitro study, exebacase was profiled against clinical Staphylococcus aureus (S. aureus) isolates from patients with CF.

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Retrieved on: 
Thursday, January 19, 2023

BARCELONA, Spain, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Pulmobiotics SL, a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases, and the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity, today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP). These data highlight a promising new approach to treat antibiotic-resistant Pseudomonas aeruginosa lung infections, a leading cause of mortality in hospital settings, and could offer a potential alternative to the use of antibiotics that enable antibiotic resistance, a global public health crisis. Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.

Key Points: 
  • Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.
  • This publication is the first time data has been described for a live biotherapeutic for the treatment of lung infection caused by Pseudomonas aeruginosa.
  • The results are published in Nature Biotechnology and this research is supported by the European Research Council through an H2020 project and “la Caixa” Foundation through the CaixaResearch Health Call.
  • Treatment led to a significant reduction in Pseudomonas aeruginosa bacterial load with the Pulmobiotics treatment alone or in combination with ceftolozane/taxobactam antibiotics.